Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) shares shot up 7.8% on Friday . The company traded as high as $11.53 and last traded at $11.47. 182,540 shares were traded during trading, a decline of 45% from the average session volume of 334,687 shares. The stock had previously closed at $10.64.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded shares of Upstream Bio from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Upstream Bio presently has an average rating of "Moderate Buy" and a consensus price target of $56.50.
Check Out Our Latest Research Report on UPB
Upstream Bio Stock Up 5.0%
The firm's 50-day moving average price is $9.47 and its 200 day moving average price is $10.85.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.71 million. Sell-side analysts predict that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.
Institutional Trading of Upstream Bio
A number of hedge funds have recently added to or reduced their stakes in UPB. FMR LLC bought a new position in shares of Upstream Bio in the 4th quarter valued at $117,977,000. Orbimed Advisors LLC bought a new stake in Upstream Bio during the 4th quarter worth $93,603,000. Decheng Capital LLC acquired a new position in Upstream Bio in the 4th quarter worth about $54,010,000. TCG Crossover Management LLC bought a new position in Upstream Bio in the fourth quarter valued at about $44,856,000. Finally, Enavate Sciences GP LLC acquired a new stake in shares of Upstream Bio during the fourth quarter valued at about $40,438,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
